

Shreemanta K Parida

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8200484/publications.pdf>

Version: 2024-02-01

42
papers

3,566
citations

172457

29
h-index

276875

41
g-index

44
all docs

44
docs citations

44
times ranked

4991
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | A blood RNA signature for tuberculosis disease risk: a prospective cohort study. <i>Lancet, The</i> , 2016, 387, 2312-2322. | 13.7 | 678 |
| 2 | Toll-like receptor pathways in the immune responses to mycobacteria. <i>Microbes and Infection</i> , 2004, 6, 946-959. | 1.9 | 234 |
| 3 | Four-Gene Pan-African Blood Signature Predicts Progression to Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1198-1208. | 5.6 | 217 |
| 4 | Biomarkers of Inflammation, Immunosuppression and Stress Are Revealed by Metabolomic Profiling of Tuberculosis Patients. <i>PLoS ONE</i> , 2012, 7, e40221. | 2.5 | 195 |
| 5 | Biomarkers for tuberculosis disease activity, cure, and relapse. <i>Lancet Infectious Diseases, The</i> , 2009, 9, 162-172. | 9.1 | 164 |
| 6 | Internalin B is essential for adhesion and mediates the invasion of <i>Listeria monocytogenes</i> into human endothelial cells. <i>Molecular Microbiology</i> , 2002, 28, 81-93. | 2.5 | 155 |
| 7 | Immunogenicity of Novel DosR Regulon-Encoded Candidate Antigens of <i>Mycobacterium tuberculosis</i> in Three High-Burden Populations in Africa. <i>Vaccine Journal</i> , 2009, 16, 1203-1212. | 3.1 | 148 |
| 8 | An Evaluation of Commercial Fluorescent Bead-Based Luminex Cytokine Assays. <i>PLoS ONE</i> , 2008, 3, e2535. | 2.5 | 137 |
| 9 | Metabolite changes in blood predict the onset of tuberculosis. <i>Nature Communications</i> , 2018, 9, 5208. | 12.8 | 129 |
| 10 | Towards host-directed therapies for tuberculosis. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 511-512. | 46.4 | 110 |
| 11 | Correlation of tumor necrosis factor levels in the serum and cerebrospinal fluid with clinical outcome in Japanese encephalitis patients. <i>Journal of Medical Virology</i> , 1997, 51, 132-136. | 5.0 | 105 |
| 12 | The quest for biomarkers in tuberculosis. <i>Drug Discovery Today</i> , 2010, 15, 148-157. | 6.4 | 105 |
| 13 | Biomarker discovery in heterogeneous tissue samples -taking the in-silico deconfounding approach. <i>BMC Bioinformatics</i> , 2010, 11, 27. | 2.6 | 95 |
| 14 | Tuberculosis in Africa: Learning from Pathogenesis for Biomarker Identification. <i>Cell Host and Microbe</i> , 2008, 4, 219-228. | 11.0 | 85 |
| 15 | Tumor necrosis factor is critical to control tuberculosis infection. <i>Microbes and Infection</i> , 2007, 9, 623-628. | 1.9 | 83 |
| 16 | Immunological Outcomes of New Tuberculosis Vaccine Trials: WHO Panel Recommendations. <i>PLoS Medicine</i> , 2008, 5, e145. | 8.4 | 82 |
| 17 | Protective effects of a recombinant fragment of human surfactant protein D in a murine model of pulmonary hypersensitivity induced by dust mite allergens. <i>Immunology Letters</i> , 2003, 86, 299-307. | 2.5 | 66 |
| 18 | Biomarkers for tuberculosis disease activity, cure, and relapse. <i>Lancet Infectious Diseases, The</i> , 2010, 10, 68-69. | 9.1 | 64 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Potential of novel Mycobacterium tuberculosis infection phase-dependent antigens in the diagnosis of TB disease in a high burden setting. BMC Infectious Diseases, 2012, 12, 10. | 2.9 | 63 |
| 20 | Novel tuberculosis vaccines on the horizon. Current Opinion in Immunology, 2010, 22, 374-384. | 5.5 | 61 |
| 21 | B in TB: B Cells as Mediators of Clinically Relevant Immune Responses in Tuberculosis. Clinical Infectious Diseases, 2015, 61, S225-S234. | 5.8 | 60 |
| 22 | Innate immunity to mycobacterial infection in mice: Critical role for toll-like receptors. Tuberculosis, 2005, 85, 395-405. | 1.9 | 56 |
| 23 | Changing funding patterns in tuberculosis. Nature Medicine, 2007, 13, 299-303. | 30.7 | 50 |
| 24 | Potential of Host Markers Produced by Infection Phase-Dependent Antigen-Stimulated Cells for the Diagnosis of Tuberculosis in a Highly Endemic Area. PLoS ONE, 2012, 7, e38501. | 2.5 | 50 |
| 25 | Analysis of Host Responses to Mycobacterium tuberculosis Antigens in a Multi-Site Study of Subjects with Different TB and HIV Infection States in Sub-Saharan Africa. PLoS ONE, 2013, 8, e74080. | 2.5 | 48 |
| 26 | T-Cell Therapy: Options for Infectious Diseases: Table 1.. Clinical Infectious Diseases, 2015, 61, S217-S224. | 5.8 | 42 |
| 27 | Immunometabolic Signatures Predict Risk of Progression to Active Tuberculosis and Disease Outcome. Frontiers in Immunology, 2019, 10, 527. | 4.8 | 40 |
| 28 | Serum tumor necrosis factor and interleukin 1 in leprosy and during lepra reactions. Clinical Immunology and Immunopathology, 1992, 63, 23-27. | 2.0 | 38 |
| 29 | Surgical Treatment of Complications of Pulmonary Tuberculosis, including Drug-Resistant Tuberculosis. International Journal of Infectious Diseases, 2015, 32, 61-67. | 3.3 | 34 |
| 30 | Dendritic Cells Activate and Mature after Infection with Mycobacterium tuberculosis. BMC Research Notes, 2011, 4, 247. | 1.4 | 30 |
| 31 | Cellular therapy in Tuberculosis. International Journal of Infectious Diseases, 2015, 32, 32-38. | 3.3 | 26 |
| 32 | The Immunological Footprint of Mycobacterium tuberculosis T-cell Epitope Recognition. Journal of Infectious Diseases, 2012, 205, S301-S315. | 4.0 | 24 |
| 33 | Novel Bacterial Delivery System with Attenuated Salmonella typhimurium Carrying Plasmid Encoding Mtb Antigen 85A for Mucosal Immunization: Establishment of Proof of Principle in TB Mouse Model. Annals of the New York Academy of Sciences, 2005, 1056, 366-378. | 3.8 | 19 |
| 34 | Infectious diseases biobanking as a catalyst towards personalized medicine: Mycobacterium tuberculosis paradigm. Tuberculosis, 2011, 91, 524-532. | 1.9 | 14 |
| 35 | Development of a potent invigorator of immune responses endowed with both preventive and therapeutic properties. Biologics: Targets and Therapy, 2017, Volume 11, 55-63. | 3.2 | 14 |
| 36 | Reduced Local Growth and Spread but Preserved Pathogenicity of a $\hat{\Gamma}$ purC Mycobacterium tuberculosis Auxotrophic Mutant in Gamma Interferon Receptor-Deficient Mice after Aerosol Infection. Infection and Immunity, 2005, 73, 666-670. | 2.2 | 9 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Mycobacterium tuberculosis proteins involved in cell wall lipid biosynthesis improve BCG vaccine efficacy in a murine TB model. International Journal of Infectious Diseases, 2017, 56, 274-282. | 3.3 | 8 |
| 38 | Toll-Like Receptors and Control of Mycobacterial Infection in Mice. Novartis Foundation Symposium, 0, , 127-141. | 1.1 | 8 |
| 39 | Landscape of Manufacturing Process of ATMP Cell Therapy Products for Unmet Clinical Needs. , 0, , . | | 6 |
| 40 | Acute respiratory distress syndrome (ARDS) as an adverse event following immunization: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine, 2021, 39, 3028-3036. | 3.8 | 5 |
| 41 | True facets of TB diagnosis in 2012: Hypes and realities. European Journal of Microbiology and Immunology, 2012, 2, 275-281. | 2.8 | 4 |
| 42 | A Decade of Interferon- γ Release Assays: Quest for the Holy Grail to Diagnose Latent Infection with Mycobacterium tuberculosis?. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1732-1732. | 5.6 | 1 |